AI Consensus Investment Thesis
TMDX: TransMedics Group Stock Price, Analysis & Forecast: 1 Year and 5 Year Targets
TransMedics Group: 1-Year and 5-Year Forecast Outlook and Rating
TransMedics Group (TMDX) has an immediate Strong Buy & Keep consensus AI recommendation, based on 14 AI analysts.
The 1-year target is $96.7 for , with +29.36% expected return (+29.36% including net dividends) and a STRONG BUY rating.
The 5-year target is $183 for , with +144.82% expected return (+144.82% including net dividends) and a BUY rating.
Latest available market price: USD 74.8, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-10-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
Targets retain their original publication dates. Returns use the dated market close and the time remaining to each fixed target date. Current ratings also require fresh quotes and analysis, with more than 90 days remaining. Past targets have no forward return. Eligibility checked .
TransMedics Group Flagship Insight
Integrated Organ Perfusion Network Balances High Capital Intensity Against Monopolistic Moats
Synthesizing input evaluations reveals high consensus that clinical dominance and turnkey aviation infrastructure create an insurmountable distribution moat. Sharp divergence persists regarding whether elevated flight operating expenses and capital intensity will permanently cap operating margins or yield substantial operating leverage at scale.
How were the Investment Thesis and Forecasts created?
14 AI advisors, guided by 9 analytical frameworks, contribute to the deep analysis by iPulse AI Engine.
Universal Investor (Polymath)
Machiavelli (Insider)
Elon Musk (Visionary)
Michael Burry (Vulture)
Warren Buffett (Value Purist)
Sherlock Holmes (Whistleblower)
Ray Dalio (Strategist)
Superintelligence (Anthropologist)
J.P. Morgan (Titan)
Ran across these frontier AI models
Google Gemini 3.8 Flash
OpenAI GPT-6 Astra
Anthropic Claude Opus 5
Latest published deep-analysis batch. Audit published forecasts in full transparency
TransMedics Group: forecast questions
What is TransMedics Group (TMDX)'s 1-year price forecast?
TransMedics Group's 1-year target is $96.7 for Sept 2027. The current AI rating is STRONG BUY. The expected return from the recorded close is +29.36%, or +29.36% modeled return including net dividends. Latest available market price: USD 74.8, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is TransMedics Group (TMDX)'s 5-year price forecast?
TransMedics Group's 5-year target is $183 for Sept 2031. The current AI rating is BUY. The expected return from the recorded close is +144.82%, or +144.82% modeled return including net dividends. Latest available market price: USD 74.8, as of 20 Oct 2026. The target date is fixed; this is not a new rolling forecast.
What is the return basis?
Latest available market price: USD 74.8, as of 20 Oct 2026. These are model projections, not guaranteed future prices.
How can I compare the AI opinions and audit past TransMedics Group forecasts?
14 AI analysts contribute to this publication. AI Opinions shows individual advisor forecasts and reasoning. Forecast History preserves earlier published batches; their figures describe their original publication, not today's outlook.
How does an AI-generated forecast for TransMedics Group differ from Wall Street analyst consensus?
Wall Street consensus aggregates estimates from human analysts. For listed companies, these typically include brokerage price targets, earnings forecasts and ratings. iPulse AI's forecast for TransMedics Group is a separate AI consensus generated through its own research workflow. Different inputs, forecast dates, assumptions and weighting can therefore produce different targets.
We believe the era of investment research conducted only by human analysts is drawing to a close. Frontier models increasingly match or exceed expert work on selected professional benchmarks, including evaluations covering financial analysis. Research on multi-model synthesis also shows that combining model responses can improve on a single model's output in the tasks studied.
iPulse AI generates transparent investment research and market forecasts using a swarm of AI configurations, analytical frameworks and frontier models. The workflow applies multiple verification, challenge and synthesis layers, with selective editorial review under Russlan Ramdowar, Editor-in-Chief. Published assumptions, disagreements and past forecasts remain available so readers can inspect the reasoning and audit outcomes.
For a research cycle covering 426 assets with 14 perspectives per asset, our internal workload model estimates approximately 114,000 hours of traditional analyst work. It assumes 16 hours per individual research report, 28 hours per consensus for synthesis and validation, plus shared data preparation. Parallel AI execution allows a deep-analysis cycle across hundreds of assets to complete in up to one day. The human-hours figure is an illustrative workload estimate, rather than measured time savings. Our research methodology explains the automated workflow.
TransMedics Group: Investment Thesis Summary
Dotted terms link to the glossary; hover or focus for a preview. Browse technical terms
If you invest $10,000 in TransMedics Group at the latest market close (20 Oct 2026): $24,482 by Sept 2031 versus $13,751 for S&P 500 benchmark.
Returns use the same dated market close, fixed targets and remaining dividend period as the forecast table.
TransMedics presents a compelling multi-organ infrastructure platform transitioning through an intensive capital-digestion phase. The core economic argument rests on the company's captive National OCS Program (NOP), where vertical integration of surgical retrieval and an owned 22-aircraft fleet creates an insurmountable distribution moat. Clinical superiority in resuscitating donation-after-circulatory-death (DCD) hearts and livers drives resilient 20% top-line compounding, protected by Medicare's statutory organ acquisition pass-through reimbursement. However, the valuation remains highly sensitive to cost-of-capital headwinds and aviation asset drag. The market must normalize for the non-recurring $82.8M tax allowance release in 2025, revealing true trailing operating earnings near $68M. The strongest counterargument highlights the economic penalty of running a dedicated air carrier: service revenue (41% of sales) structurally dilutes gross margins, while unhedged jet fuel volatility, aircraft maintenance, and emerging hospital-based normothermic regional perfusion (NRP) protocols cap terminal margins below management's 30% target.
Key insights
- Captive aviation assets transform fixed logistics overhead into an expanding switching barrier that standalone hardware competitors cannot breach without massive capital destruction.
- Growth mix dilution poses structural friction: service revenues compound faster than high-margin consumable cassettes, permanently altering the normalized operating margin profile.
- Approaching 2028 convertible note maturities requires disciplined operational cash generation to prevent punitive debt refinancing in a higher-for-longer interest rate regime.
TransMedics Group: 5 Year Consensus Forecast
20 quarterly price targets, returns and rationale, with advisor range and benchmark
Forward returns are updated using the latest market close price of USD 74.8, as of 20 Oct 2026.
Dividend calculation details
Calculated net annual dividend yield: 0%. As of 2026-10-20.
Gross TTM: 0% · Two-year annualized gross: 0%.
Tax withholding assumption: 30% (US). One-off special payments are excluded.
Return estimates compound the net annual yield at a constant rate over the stated return horizon (the remaining time to the fixed target date for current returns): (1 + price return) × (1 + net annual yield)years − 1.
The consensus target follows an expert-weighted price path synthesized from 14 AI advisor opinions. See Opinion weights and rationale for the exact allocation and reasoning.
Forecast methodology and reference values
Published targets are anchored on 18 Sept 2026 at USD 86.4. Original quarter-to-quarter target changes are retained. Forward returns use the remaining time to each fixed target date.
The pessimistic and optimistic advisor base cases are the lowest and highest published advisor base-case targets for each quarter. The advisor at either extreme can change between quarters. Benchmark values are in USD.
Scroll the table horizontally to read every column.
| Quarter | Evidence-Weighted Consensus Price Path | Individual Advisor Range & Reference Forecasts | ||||||
|---|---|---|---|---|---|---|---|---|
| Consensus target (USD) | Forecast quarter-to-quarter price change | Forward price return | Forward return incl. net dividends | Forecast rationale | Pessimistic Advisor Base Case (USD) | Optimistic Advisor Base Case (USD) | S&P 500 benchmark (USD) | |
| $86.7 | +0.34% | +15.99% | +15.99% | Q3 results confirm solid procedural volume expansion across liver and heart programs, but elevated jet fuel expenses and executive transition noise keep quarterly operating margins compressed, resulting in flat-to-modest equity performance. | $81.2 | $90.7 | $750 | |
| $89.8 | +3.58% | +20.13% | +20.13% | Full-year 2026 results confirm top-line execution near $745M. Normalization of reported trailing net income without prior tax credits tempers multiple expansion, though constructive 2027 guidance establishes a resilient valuation floor. | $78.8 | $95.3 | $736 | |
| $94.1 | +4.77% | +25.89% | +25.89% | Sequential gross margin stabilization emerges as fuel surcharges take effect and flight route scheduling improves across domestic hubs. Core liver cassette replenishment offsets initial PAD Aviation European integration costs. | $82.8 | $103 | $743 | |
| $96.7 | +2.74% | +29.36% | +29.36% | Summer procurement seasonality and elevated clinical trial expenditures for ENHANCE and DENOVO produce modest margin consolidation, counterbalanced by steady double-digit procedural volume growth across certified transplant centers. | $86.1 | $108 | $755 | |
| $103 | +6.43% | +37.79% | +37.79% | Strong year-end transplant volume combines with initial commercial cross-border flight missions in Western Europe. Growing cassette pull-through improves service unit economics, prompting moderate institutional accumulation. | $91.2 | $116 | $776 | |
| $108 | +4.49% | +44.48% | +44.48% | Full-year 2027 earnings demonstrate sequential operating margin recovery toward 15%. Investor attention pivots to the approaching June 2028 convertible note maturity, keeping valuation multiples disciplined despite solid cash generation. | $94.0 | $126 | $787 | |
| $112 | +4.23% | +49.83% | +49.83% | TransMedics addresses its $460M convertible notes through structured refinancing. Resolving balance-sheet overhang without punitive equity dilution triggers a relief rally, supported by accelerating European operational contributions. | $95.3 | $134 | $803 | |
| $117 | +4.11% | +56.52% | +56.52% | Optimized aviation route density across domestic corridors lowers deadhead flight hours. Steady recurring consumable cassette sales sustain operating profits, absorbing scheduled aircraft maintenance without cash flow impairment. | $102 | $135 | $812 | |
| $124 | +5.89% | +65.89% | +65.89% | Pivotal clinical progress across heart and lung trials reinforces clinical exclusivity over static cold storage. Fiscal 2028 concludes with revenue approaching $1B, validating multi-organ platform adoption. | $107 | $141 | $839 | |
| $129 | +4.64% | +72.58% | +72.58% | Full-year 2028 financials confirm operating margins approaching 18% as fixed aviation overhead amortizes. Initial premarket regulatory milestones for OCS Kidney attract long-term healthcare growth allocators. | $104 | $154 | $851 | |
| $136 | +5.07% | +81.94% | +81.94% | Submission of formal PMA filings for OCS Kidney sparks multiple expansion as the addressable market narrative widens. European NOP operations achieve operating breakeven, demonstrating successful international model exportability. | $109 | $166 | $872 | |
| $140 | +2.73% | +87.29% | +87.29% | Transplant center budgeting cycles and competitive marketing from hypothermic perfusion alternatives create minor pricing friction, temporarily moderating quarterly sequential earnings growth in standard donor indications. | $113 | $174 | $886 | |
| $147 | +5.25% | +96.66% | +96.66% | Robust fourth-quarter organ retrievals and expanding DCD heart utilization drive record consumable kit shipments. Free cash flow generation accelerates, enabling internal funding of next-generation console tooling. | $118 | $182 | $910 | |
| $153 | +4.50% | +104.68% | +104.68% | Annual 2029 results validate durable twenty percent operating margins. Cash reserves accumulate, reinforcing balance sheet strength and proving that captive logistics creates an enduring competitive barrier. | $121 | $193 | $916 | |
| $159 | +3.65% | +112.71% | +112.71% | Regulatory clearance for OCS Kidney initiates controlled commercial deployment across high-volume renal transplant centers. Incremental consumable sales leverage existing flight infrastructure, expanding gross profit margins. | $126 | $208 | $937 | |
| $162 | +1.88% | +116.72% | +116.72% | Routine periodic aircraft engine overhauls and commercial launch expenditures for kidney perfusion induce modest margin digestion, allowing the market to consolidate substantial multi-year share price gains. | $127 | $202 | $947 | |
| $169 | +4.11% | +126.09% | +126.09% | Accelerating kidney cassette adoption combines with mature liver franchise dominance. Procedural volume compounds predictably, driving full-year revenue well above $1.3B and lifting operating cash flows. | $134 | $212 | $970 | |
| $174 | +3.15% | +132.78% | +132.78% | Full-year 2030 financial reporting showcases normalized operating margins exceeding 22%. European operations deliver sustained profit contributions, broadening the enterprise beyond its domestic foundation. | $136 | $220 | $980 | |
| $178 | +2.15% | +138.13% | +138.13% | Mature fleet operations achieve peak logistics efficiency. Established standard-of-care status in warm machine perfusion insulates the company from macro volatility, supporting steady earnings compounding. | $140 | $229 | $1,000 | |
| $183 | +2.94% | +144.82% | +144.82% | TransMedics concludes the forecast period established as an indispensable organ procurement utility. Valuation settles at a mature infrastructure-like multiple supported by robust recurring cash generation. | $143 | $238 | $1,012 | |
Show remaining 18 quartersShow first 2 quarters only
All 20 quarters are displayed in the table above.
TransMedics Group Stock Analysis & Scenarios Deep Dive
TransMedics Group: Alpha Gap & Repricing Catalysts
Market Narrative
What does the market currently expect? Outside market consensus views TransMedics as a decelerating medtech pioneer that compromised its corporate quality by transforming into a capital-heavy regional airline. Sell-side commentary fixates on Q2 2026 GAAP net income contraction, ongoing CFO turnover, and margin dilution from jet fuel and R&D outlays, anchoring on the belief that running aviation logistics permanently caps operating profitability below historical device industry standards.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underprices TransMedics' durable operational edge by mistaking a planned infrastructure reinvestment phase for terminal margin decay. While the market overreacts to the optical drop from tax-distorted 2025 earnings, it overlooks how captive aviation creates an inescapable distribution monopoly over nationwide donor recovery. The strongest challenge is that service revenue genuinely carries lower gross margins than consumables; however, route-density optimization will unlock substantial operating leverage as case volumes scale.
Repricing Catalyst
What could make the market recognize and close that gap? Sequential gross margin stabilization above 60% and operating margin recovery toward 16% across 2027 filings will trigger market repricing. Observable inflection points include the clinical data readout and IDE milestones for the OCS Kidney platform alongside operating breakeven in European flight operations via PAD Aviation. These operational receipts will prove to skeptical analysts that aviation logistics dilutes fixed costs rather than permanently impairs profitability.
TransMedics Group: Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed and Fear Sentiment
- Fear
- Volatility Regime
- High Erratic
- Convergence Cycle Position
- Stabilization
Perspectives align on prevailing investor fear stemming from margin compression and CFO turnover. The key disagreement centers on whether the cycle is at a cyclical valuation bottom or facing a multi-year derating as airline economics dilute medtech premiums.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regime of 3.75%-4.00% policy rates and elevated jet fuel prices acts as a tangible operational headwind. High interest rates raise the equity hurdle rate and refinancing costs for the 2028 convertible notes, while expensive fuel compresses flight margins. However, end-stage organ failure is clinically non-discretionary, completely insulating core procedure volumes from macroeconomic deceleration.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement centers on the terminal margin profile and capital intensity of TransMedics' hybrid model. Bullish perspectives argue that aviation fleet investments represent a completed capital phase that will unlock operating margins above 25% through route density. Conversely, conservative analysts view owned aviation as a perpetual operational friction where jet fuel, aircraft depreciation, and crew payroll permanently cap operating margins near 14% to 16%. Observing whether quarterly service gross margins can sequentially surpass 40% while maintaining volume growth will definitively resolve whether logistics acts as an operating flywheel or a permanent margin anchor.
TransMedics Group: Critical Influencing Factors
Near-certain positive forcesTop Drivers & Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Captive Aviation Logistics Distribution Moat | Competitive Positioning | +34% | +42% | Controlling 22 dedicated transport aircraft allows TransMedics to cover over 80% of domestic National OCS Program missions internally. This end-to-end integration eliminates charter broker markups and guarantees surgical retrieval timing. Standalone device makers cannot replicate this physical distribution network without immense capital destruction, locking in dominant hospital market share. |
| DCD Donor Organ Utilization Expansion | Sector And Industry | +28% | +38% | Secular clinical adoption of donation-after-circulatory-death (DCD) donors drives steady volume expansion across heart and liver indications. Because marginal organs deteriorate rapidly in static cold storage, warm perfusion is becoming the clinical standard of care. This biological necessity compounds high-margin recurring single-use cassette sales at roughly 20% annually. |
| Statutory Organ Acquisition Pass-Through Reimbursement | Regulatory | +22% | +26% | TransMedics' pricing power is structurally insulated by Medicare Title XVIII provisions, allowing certified transplant centers to pass organ procurement and transportation expenses directly to federal trust funds without standard DRG caps. Regulatory mandates penalizing organ discards further incentivize transplant centers to deploy OCS regardless of upfront procedure costs. |
| Aviation Fleet Density Operating Leverage | Operational Efficiency | +20% | +28% | Having absorbed initial aircraft acquisition capital expenditures, TransMedics is shifting toward flight asset optimization. Increasing annual flight hours per airframe amortizes fixed pilot compensation and maintenance overhead across higher mission counts. This route-density scaling expands service gross margins toward 38%, transforming transport logistics into an accretive earnings contributor. |
Near-certain negative forcesTop Frictions & Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Aviation Asset Intensity Margin Dilution | Operational Efficiency | -20% | -25% | Service revenue expanding to 41% of sales structurally dilutes blended profitability because logistics generates lower gross margins than consumable cassettes. Operating an owned air fleet exposes earnings to mandatory FAA maintenance overhauls, pilot payroll inflation, and unhedged jet fuel price spikes, capping consolidated operating margins below historic software-like expectations. |
| Normothermic Regional Perfusion Clinical Substitution | Competitive Positioning | -16% | -18% | Transplant centers are increasingly deploying hospital-based normothermic regional perfusion (NRP) using existing ECMO circuits for in situ DCD donor resuscitation. Because NRP bypasses TransMedics' expensive proprietary disposables and private flight charters for regional recoveries, it caps OCS volume penetration in cost-conscious academic medical centers. |
| Convertible Debt Refinancing Hurdle | Macroeconomic And Macrofinancial | -15% | -12% | TransMedics faces a $460 million convertible senior note maturity on June 1, 2028, carrying a 1.50% coupon. In an elevated monetary policy regime with benchmark yields near 4%, refinancing or cash-settling this obligation threatens to consume operational cash flow, raise interest expense, or impose equity dilution on existing shareholders. |
| Front-Loaded Clinical Research Expenditure Drag | Capital Allocation | -12% | -16% | Quarterly R&D expenses nearly doubled year-over-year to over $31 million in mid-2026 to support next-generation console architectures and pivotal trials. While necessary to expand indications, heavy trial-related outlays and clinical solution costs depress near-term GAAP operating income and return on capital during the intermediate pipeline gestation window. |
TransMedics Group: What Could Break or Accelerate the Thesis
Event Risk Score: Moderate 58/100Asset-level relative pressure from clustered consensus frictions and tail risks. This is not the probability or risk score of an individual force.Plausible downside scenariosTail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Catastrophic Aviation Fleet Grounding Directive | 14% | -42% | A fatal crash or severe airworthiness directive across TransMedics' dedicated jet fleet prompting an emergency FAA grounding would instantly paralyze the National OCS Program. Halting flight operations would strand donor organs, destroy customer clinical trust, spike liability insurance costs, and wipe out tens of millions in logistics revenue within months. |
| Medicare Organ Acquisition Reimbursement Cap | 26% | -36% | The Centers for Medicare and Medicaid Services could initiate targeted cost-containment audits restricting pass-through allowances for private air charter markups and perfusion disposables. Imposing fixed prospective payment limits would force transplant centers to absorb logistics cost overruns, triggering immediate clinical pushback and steep price discounting. |
Plausible upside scenariosTail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| OCS Kidney Accelerated PMA Clearance | 35% | +52% | Securing accelerated FDA Premarket Approval for the OCS Kidney platform around 2028 would quadruple TransMedics' total addressable market, as kidney transplants exceed 25,000 annual US procedures. Commercialization would utilize the existing aviation network with negligible incremental transport capex, unlocking massive high-margin cassette pull-through and driving corporate operating margins above 25%. |
| Mandatory Federal Warm Perfusion Standard | 25% | +38% | Federal healthcare authorities could establish mandatory quality metrics penalizing organ procurement organizations for organ discard rates while providing enhanced DRG add-on payments for machine perfusion by 2028. Obsoleting static cold storage would eliminate hospital procurement discretion, locking in TransMedics as a statutory standard of care across nationwide organ recovery. |
Company Financial AnalysisTransMedics Group: Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included. View latest TransMedics Group financials here.
Earnings and financials
TransMedics has demonstrated powerful top-line revenue growth, expanding annual sales by 37.1% to $605.5 million in fiscal 2025 and continuing with 20.7% growth to $189.9 million in the second quarter of 2026. However, reported net income paints a confusing picture for investors. While 2025 headline net income reached $190.3 million, that figure was artificially boosted by a one-off, non-cash tax benefit of $82.8 million. Normalized earnings were closer to $68 million. In the first half of 2026, GAAP profits dropped sharply to $14.7 million as research spending nearly doubled to develop new kidney platforms and fleet maintenance costs increased. This decline does not mean customer demand is falling; underlying procedure volumes remain robust. Operating cash generation remains positive at $79 million over the trailing twelve months, showing that the core business is self-funding its heavy growth investments.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 605.5M | USD 190.3M | USD 133.6M |
| 2024 | USD 441.5M | USD 35.5M | USD -80.9M |
| 2023 | USD 241.6M | USD -25M | USD -192.1M |
| 2022 | USD 93.5M | USD -36.2M | USD -57.7M |
| 2021 | USD 30.3M | USD -44.2M | USD -32.4M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 26.2x | TTM | Native | USD / USD |
| 2024 | 61.9x | TTM | Native | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
TransMedics exhibits a sharp divide between steady gross margins and fluctuating operating profits. Gross margins have held firm near 59.6%, demonstrating strong pricing power for single-use organ preservation cassettes. However, operating margin compressed from 17.9% in 2025 to 12.5% in mid-2026. This contraction is driven by two factors: lower-margin aviation logistics rising to 41% of total sales, and elevated jet fuel prices. This margin compression represents active business reinvestment rather than permanent deterioration. Single-use organ cassettes generate high gross profits, but flight logistics dilute corporate margins. Long-term profitability will depend on route density; as aircraft fly more missions per month and higher-margin kidney cassettes eventually launch, fixed transport costs will dilute, allowing operating margins to climb back toward the low-twenties percentage range.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 108.6M | 17.9% | 31.4% |
| 2024 | USD 37.5M | 8.5% | 8.0% |
| 2023 | USD -28.7M | -11.9% | -10.4% |
| 2022 | USD -31.4M | -33.6% | -38.8% |
| 2021 | USD -39.4M | -130.3% | -146.1% |
Balance sheet and leverage
On the surface, TransMedics appears to hold a fortress balance sheet, with roughly $473 million in cash and short-term liquidity alongside a current ratio of 7.14 at mid-2026. Total stockholders' equity reached $473 million, and headline debt-to-equity declined to 0.99. This substantial cash buffer provides crucial breathing room, ensuring the company can advance clinical trials without needing desperate equity raises. However, deeper inspection reveals significant structural commitments. The company carries $460 million in convertible notes that mature in June 2028, alongside substantial aircraft lease and facility obligations. Total financing commitments approach $862 million, leaving net financing obligations near $389 million. Refinancing the 2028 notes in a higher interest rate environment represents management's primary financial hurdle, requiring steady operational cash flow to avoid expensive borrowing or shareholder dilution.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Reported net cash / (debt) | Debt less (cash + short-term investments), calculated | Current ratio |
|---|---|---|---|---|---|
| 2025 | USD 469.7M | USD 488.4M | USD 18.7M net cash | USD -18.7M | 7.14x |
| 2024 | USD 518.3M | USD 336.7M | USD 181.6M net debt | USD 181.6M | 8.30x |
| 2023 | USD 515.9M | USD 394.8M | USD 121.1M net debt | USD 121.1M | 9.30x |
| 2022 | USD 67.6M | USD 201.2M | USD 133.6M net cash | USD -133.6M | 10.66x |
| 2021 | USD 43.8M | USD 92.5M | USD 17M net cash | USD -48.7M | 5.11x |
Reported net debt retains the source definition, which can deduct cash alone. Cash plus short-term investments is broader liquidity; the separately calculated column subtracts that full amount from total debt for the same fiscal period and currency. Reported net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
Management has spent recent years transforming the company from a medical equipment seller into an integrated logistics network. Direct cash spending on equipment peaked at 29.4% of revenue in 2024 as TransMedics assembled its private fleet of 22 aircraft, before normalizing to 9.8% in 2025. In 2026, capital deployment shifted toward establishing a European flight hub through Germany-based PAD Aviation and leasing a centralized corporate campus. While operating aircraft requires ongoing engine maintenance and specialized inspections, owning transport infrastructure creates an insurmountable barrier against competitors who rely on commercial flights. Spending has migrated from buying planes into research and development, which climbed 98.5% year-over-year in the second quarter of 2026. The economic payoff depends on spreading these heavy fixed infrastructure expenses across significantly more transplant missions over the coming years.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 59.3M | USD 69.1M |
| 2024 | USD 129.7M | USD 56M |
| 2023 | USD 179.1M | USD 63.3M |
| 2022 | USD 11.9M | USD 26.8M |
| 2021 | USD 3.5M | USD 22.3M |
Behind the synthesisTransMedics Group: How Each Individual AI Forecaster Opinion Shapes the Global Consensus
This publication’s recorded synthesis allocated voting influence across 14 advisor opinions. The weights and rationales below are retained from that synthesis.
The common causal pattern across reports recognizes TransMedics' transition from an asset-light medtech innovator to an integrated organ procurement utility operating a dedicated 22-aircraft aviation fleet. Top-line volume growth remains robust at roughly 20% year-over-year, supported by non-discretionary organ transplant demand and Medicare pass-through reimbursement. However, the reports heavily diverge on the duration of margin dilution. Correlated bullish assumptions treat aviation infrastructure as a temporary margin drag that will automatically generate software-like operating leverage as mission density compounds. The strongest credible contrarian case, prioritized in weighting, demonstrates that service revenue at 41% of sales carries structurally lower margins, while headline 2025 net income was inflated by an $82.8M non-cash tax allowance release. High weights are allocated to reports grounding their valuation in normalized earnings power (~$68M) and recognizing the impending June 2028 convertible note maturity amid 4% benchmark rates. Reports assuming frictionless OCS Kidney approval or extreme multiple expansion without acknowledging capital intensity are downweighted.
All 14 opinions
Universal Investor AI
The Polymath
Anthropic Claude Opus 5 · 2026-07-24 releaseWeight: 10.6%
Exceptional evidentiary rigor supported by SEC filings and clinical registry data. Accurately highlights that service growth dilutes corporate margins while distinguishing genuine $68M trailing cash earnings power from non-cash tax releases, setting a balanced valuation baseline.
Universal Investor AI
The Polymath
OpenAI GPT-6 Astra · 2026-09-03 releaseWeight: 10.6%
Methodically grounded in primary SEC 10-K and 10-Q disclosures. Correctly identifies $389M in net financing obligations including finance leases, models the non-additive nature of factor impacts, and properly excludes unproven OCS Kidney cash flows from base valuation.
Michael Burry AI
The Vulture
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 8.8%
Provides rigorous forensic scrutiny of normalized earnings, properly stripping out the 2025 tax valuation allowance release and evaluating the June 2028 convertible maturity. The capital-intensity penalty is causally sound, balancing unbridled clinical optimism.
Sherlock Holmes AI
The Whistleblower
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.1%
Articulates strong operational insights regarding disposable cassette pull-through and aviation leverage. However, its baseline projections overly rely on frictionless OCS Kidney regulatory execution and downplay near-term margin dilution from aviation maintenance and fuel overhead.
Niccolo Machiavelli AI
The Insider
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.1%
Offers valuable institutional analysis of Medicare Title XVIII pass-through mechanics, political scrutiny from HHS-OIG, and in situ normothermic regional perfusion competition. The regulatory friction analysis provides essential ballast against unconstrained volume growth assumptions.
Elon Musk AI
The Visionary
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 7.1%
Excellent first-principles critique of aviation asset intensity and thermodynamic realities contrasted with captive distribution power. The thesis correctly identifies execution velocity while cautioning against governance friction from recent CFO turnover.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.2%
Accurately captures the durable economic moat created by integrated organ logistics and non-discretionary clinical demand. However, it underweights the drag of elevated interest rates on long-duration medtech multiples and aviation fuel pass-through lags.
Ray Dalio AI
The Strategist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.2%
Presents a solid macroeconomic framing of capital deepening and European network scaling via PAD Aviation. Nevertheless, its long-term operating margin projections toward 26% appear overly optimistic given persistent aviation maintenance and crew cost burdens.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.2%
Constructs a robust argument around biological necessity and physical distribution bottlenecks. However, it somewhat brushes aside near-term convertible refinancing vulnerabilities and overstates the rapidity of automated console margin benefits.
Warren Buffett AI
The Value Seeker
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.2%
Demonstrates sound understanding of the razor-and-blade model across liver and thoracic indications. However, its valuation estimates place excessive faith in rapid multiple recovery while discounting ongoing competitive pressure from hypothermic alternatives.
J.P. Morgan AI
The Titan
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.2%
Strong articulation of the infrastructure monopoly narrative and potential commercial TAM unlock from OCS Kidney. However, its 2031 compounded equity appreciation estimate overshoots reasonable capital-intensity and discount-rate constraints.
Superintelligence AI
The Anthropologist
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.2%
Solid synthesis of transatlantic expansion, clinical trial pipelines (ENHANCE and DENOVO), and balance sheet liquidity. Yet it mildly underestimates the persistent margin dilution stemming from rising service revenue mix.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 6.2%
Effectively models the capital expenditure cycle trough and DCD organ expansion drivers. However, its long-term free cash flow compounding path understates competitive encroachment from Terumo/OrganOx and regional in situ perfusion protocols.
Universal Investor AI
The Polymath
Google Gemini 3.8 Flash · 2026-09-02 releaseWeight: 5.3%
Clear focus on the fixed-cost absorption flywheel and clinical trial catalysts. However, it assigns insufficient probability to potential Medicare reimbursement pushback against bundled aviation transport logistics fees.
References & Context
Research Provenance
Analysis generated by iPulse AI Engine v7 using recorded market data, operating under the editorial standards and supervision of Russlan Ramdowar, Editor-in-Chief.
External references below are sources recorded by the researcher agents for this TransMedics Group forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher web26 available sources from this batch (48 recorded). The first 15 are shown below; expand to read the rest.
- Building a Safer, More Accountable Transplant System | HRSA hrsa.gov
- Modernizing the Transplant System Through Safety and Transparency | HRSA hrsa.gov
- From Haphazard to a Sustainable Normothermic Regional Perfusion Service: A Blueprint for the Introduction of Novel Perfusion Technologies ncbi.nlm.nih.gov
- Thoracoabdominal Normothermic Regional Perfusion: Real-world Experience and Outcomes of DCD Liver Transplantation ncbi.nlm.nih.gov
- Real‐World Use of Normothermic Machine Perfusion in Liver Transplantation: A Multi‐Institutional Experience From the National Organ Perfusion Registry - PMC pmc.ncbi.nlm.nih.gov
- 10-K sec.gov
- TransMedics Group, Inc. - Form 10-Q - FY2026 sec.gov
- TMDX Q2-2026 Earnings Call - Alpha Spread alphaspread.com
- transmedics reports fourth quarter and full year 2025 financial results barchart.com
- TransMedics Group Inc (TMDX) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic ... finance.yahoo.com
- Why TransMedics Stock Is Sinking Today | The Motley Fool fool.com
- TMDX FRAUD ALERT: TransMedics Group, Inc. Investigated for Securities Fraud after Stock Drops 30% – Investors Urged to Contact BFA Law (NASDAQ:TMDX) globenewswire.com
- TMDX STOCK NEWS: TransMedics Group, Inc. 30% Stock Drop Prompts Fraud Investigation; Contact BFA Law if You Suffered Losses (NASDAQ:TMDX) globenewswire.com
- TransMedics Group Inc (TMDX) Stock Price & News - Google Finance google.com
- Earnings call transcript: TransMedics Q1 2026 earnings miss sends stock tumbling By Investing.com investing.com
Show 11 more sources
- TransMedics at 2026 Global Healthcare Conference: growth plan widens By Investing.com investing.com
- TransMedics Q2 2026 slides: revenue hits record but margins compress By Investing.com investing.com
- Microsoft PowerPoint - TMDX - 2Q 2026 Earnings Release Results_vF_08042026 investors.transmedics.com
- Microsoft PowerPoint - TMDX-Baird Conference-Sept.15.2026 v2 investors.transmedics.com
- TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook | TransMedics investors.transmedics.com
- TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results | TransMedics investors.transmedics.com
- TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results | TransMedics investors.transmedics.com
- TransMedics Reports Second Quarter 2026 Financial Results | TransMedics investors.transmedics.com
- TransMedics Group (TMDX) Stock Price & Overview stockanalysis.com
- Terumo completes acquisition of OrganOx | Terumo terumo.com
- Transmedics Group (TMDX) Q2 2026 Earnings Report - Results, Call & Slides - TipRanks.com tipranks.com
22 additional sources are recorded in this batch; their citation details are not available in this publication.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
Archived context covering 2025-01-01 to 2025-12-31. Its recorded scope includes technology and capital cycle; trade and industrial policy; monetary policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 90.8K bytes
- Words
- 13.3K words
- Characters
- 90.8K characters
- Est. tokens (characters ÷ 4)
- 22.7K tokens
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Archived context covering 2026-01-01 to 2026-09-20. Its recorded scope includes monetary policy and rates; geopolitics energy and shipping; trade and industrial policy. Selected highlights reflect the analysis cutoff, not current world conditions.
Show moreShow less
- File size
- 84.8K bytes
- Words
- 12.4K words
- Characters
- 84.8K characters
- Est. tokens (characters ÷ 4)
- 21.2K tokens
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Selected highlights from this archived snapshot | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental Context Passed as Input to the Models
Time range: Annual fiscal periods: 2016-12-31–2025-12-31, 10 periods; Quarterly fiscal periods: 2023-09-30–2026-06-30, 12 periods.
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
Show moreShow less
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.